Patients Experiencing Respiratory Articles & Analysis
52 news found
Vitalograph has joined forces with MedM Inc. to further enhance patient respiratory monitoring experience with digital health capabilities. The MedM health monitoring app is paired with Vitalograph’s Asthma-1 BT and Lung Monitor BT Smart devices. The app works as a digital asthma or lung function diary, helping users to better understand and manage their condition. Patient diaries like ...
Vitalograph is proud to announce that it a FeNO by NIOX® UK channel partner. Spirometry and FeNO present physicians with complementary diagnostic data to inform asthma care pathways. NIOX VERO® is non-invasive, simple-to-use, and provides rapid standardised FeNO measurements. It is a point-of-care device for assessing airway inflammation in patients with respiratory problems. With over ...
Vitalograph, a global leader in the development and production of respiratory diagnostic solutions and clinical trial services, has launched the Vitalograph tremoflo® C-100 at this year’s ATS International Conference, in Washington. Developed in partnership with Thorasys, the Vitalograph tremoflo® C-100 oscillometer helps to detect the presence of small airway impairment, providing ...
Vitalograph, a global leader in the development and production of respiratory diagnostic solutions and clinical trial services, has launched the Vitalograph tremoflo® C-100 at this year’s ATS International Conference, taking place in Washington. ...
Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that ...
Beyond Air, Inc. (NASDAQ: XAIR) a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced ...
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced ...
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that it ...
The initial targeted indications include: Post-operative Respiratory Depression. Respiratory depression is common in patients recovering from surgery and anesthesia. ...
N8 Medical, LLC (N8 Medical) today announced its first-in-human clinical trials of its flagship CeraShield™ endotracheal tube (CeraShield™ ETT) for intensive care unit patients expected to require mechanical ventilation for more than 48 hours. N8 Medical is encouraged by preliminary study data and believes that the CeraShield™ ETT will demonstrate safety and a significant ...
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has completed a propofol induced respiratory depression study with its lead compound ENA001, having achieved the targeted primary endpoint. ...
Why is the oxygen generator important? Oxygen is a life-saving therapeutic gas, which is often used to treat patients with severe pneumonia and other respiratory diseases. Oxygen generator is an electric medical equipment. It first inhales air, removes nitrogen, then generates a continuous oxygen source, and delivers concentrated oxygen to patients who need respiratory support in a controlled ...
Post hoc analyses conducted in patient populations at greater risk of progression to severe disease or death suggests that SNG001 may have an important clinical effect on top of standard of care Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the ...
To address the need for better chronic respiratory care, Prof De Backer, emeritus Professor Pulmonology at the University of Antwerp and Chairman of The board of FLUIDDA NV, has opened a private clinic in Belgium near the Fluidda headquarters in Kontich, Belgium. The clinic uses a multidisciplinary approach for chronic respiratory failure. Care at this private clinic can involve exercise ...
ByFluidda
OM Pharma is pleased to announce that Etienne Jornod, its Executive Chairman and co-owner, has been recognised as winner of the Swiss Biotech Success Stories Awards 2022. The awards, bestowed annually by the Swiss Biotech Association, celebrates those who have made important and sustainable contributions to the biotech industry in Switzerland. The Swiss entrepreneur was particularly ...
BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for BCDA-04, a proprietary allogeneic mesenchymal cell (MSC) population that is Neurokinin-1 receptor positive ...
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today announced that the U.S. Patent and ...
MADISON, Wis., March 2, 2022 /PRNewswire/ -- Today Redox, the company driving interoperability in healthcare, has announced a partnership with Spire Health, the leading digital healthcare company for respiratory remote patient monitoring (RPM). Together, Spire Health and Redox will integrate RPM data into health system electronic medical records (EMRs) to improve both billing and clinical ...
NDD Medical Technologies (NDD), a leading provider of diagnostic technology enabling healthcare professionals the early detection of COPD and other chronic lung diseases, has updated the entire EasyOne® product range, including the EasyOne Air, Easy on-PC, EasyOne Pro, and EasyOne Pro LAB, to be compliant with the ATS/ERS Standardization of Spirometry 2019. Spirometry is widely used in the ...